# GFM-Acadesine: A Phase I-II Trial of Acadesine

> **NCT01813838** · PHASE1,PHASE2 · TERMINATED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 5 (actual)

## Conditions studied

- SMD

## Interventions

- **DRUG:** ACADESINE 140mg/kg/d
- **DRUG:** ACADESINE 210mg/kg/d
- **DRUG:** ACADESINE 315mg/kg/d

## Key facts

- **NCT ID:** NCT01813838
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2013-06
- **Final completion:** 2015-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Renal toxicity
- **Last updated:** 2016-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813838, "GFM-Acadesine: A Phase I-II Trial of Acadesine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01813838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*